Review
Open access
Oct 2026
Modeling human neurodegeneration with iPSCs: opportunities, limitations, and the challenge of aging
Most neurodegenerative diseases reflect patient-specific combinations of polygenic risk variants interacting with aging and environmental factors, rather than a single causative mutation. Phase III clinical trial failure rates for neurodegenerative indications exceed 95%, reflecting in part the limitations of existing...
Shi-Jie Wang, L. Elia, Wei-Yi Liu et al.
· Journal of Clinical Investig... · 0 citations